Biological drugs for systemic lupus erythematosus or active lupus nephritis and rates of infectious complications. Evidence from large clinical trials.
Steiger S, Ehreiser L, Anders J, Anders HJ.
Front Immunol. 2022 Sep 23;13:999704. doi: 10.3389/fimmu.2022.999704. eCollection 2022.
Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial.
Nguyen QD, Merrill PT, Jaffe GJ, Dick AD, Kurup SK, Sheppard J, Schlaen A, Pavesio C, Cimino L, Van Calster J, Camez AA, Kwatra NV, Song AP, Kron M, Tari S, Brézin AP.
Lancet. 2016 Sep 17;388(10050):1183-92. doi: 10.1016/S0140-6736(16)31339-3. Epub 2016 Aug 16.
Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials.
van der Heijde D, Deodhar A, Baraliakos X, Brown MA, Dobashi H, Dougados M, Elewaut D, Ellis AM, Fleurinck C, Gaffney K, Gensler LS, Haroon N, Magrey M, Maksymowych WP, Marten A, Massow U, Oortgiesen M, Poddubnyy D, Rudwaleit M, Shepherd-Smith J, Tomita T, Van den Bosch F, Vaux T, Xu H.
Ann Rheum Dis. 2023 Apr;82(4):515-526. doi: 10.1136/ard-2022-223595. Epub 2023 Jan 17.
Upper Respiratory Tract Infections With Focus on The Common Cold.
Tobin EH, Thomas M, Bomar PA.
2025 May 4. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–.
Chronic adenoiditis.
Wang H.
J Int Med Res. 2020 Nov;48(11):300060520971458. doi: 10.1177/0300060520971458.
AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
Matsuoka K, Watanabe M, Ohmori T, Nakajima K, Ishida T, Ishiguro Y, Kanke K, Kobayashi K, Hirai F, Watanabe K, Mizusawa H, Kishida S, Miura Y, Ohta A, Kajioka T, Hibi T; AJM300 Study Group.
Lancet Gastroenterol Hepatol. 2022 Jul;7(7):648-657. doi: 10.1016/S2468-1253(22)00022-X. Epub 2022 Mar 30.
Infectious adverse events in patients with atopic dermatitis treated with baricitinib.
Antonelli F, Malvaso D, Caldarola G, Simone C, Peris K, Chiricozzi A.
Immunotherapy. 2023 Dec;15(18):1521-1529. doi: 10.2217/imt-2023-0078. Epub 2023 Oct 18.
Efficacy and Safety of Brodalumab, an Anti-interleukin-17 Receptor A Monoclonal Antibody, for Palmoplantar Pustulosis: 16-Week Results of a Randomized Clinical Trial.
Okubo Y, Kobayashi S, Murakami M, Sano S, Kikuta N, Ouchi Y, Terui T.
Am J Clin Dermatol. 2024 Sep;25(5):837-847. doi: 10.1007/s40257-024-00876-x. Epub 2024 Jul 2.
Infectious events in patients treated with immune checkpoint inhibitors, chimeric antigen receptor T cells, and bispecific T-cell engagers: a review of registration studies.
Lombardi A, Saydere A, Ungaro R, Bozzi G, Viero G, Bandera A, Gori A, Mondelli MU.
Int J Infect Dis. 2022 Jul;120:77-82. doi: 10.1016/j.ijid.2022.04.022. Epub 2022 Apr 13.
Infectious complications of Belimumab with standard care in systemic lupus erythematosus: a systematic review and meta-analysis.
Zhao Y, Chi G, Xia S, Wang X, Fan Y, Ma C, Wei JC, Wang W.
Semin Arthritis Rheum. 2025 Aug;73:152754. doi: 10.1016/j.semarthrit.2025.152754. Epub 2025 May 14.
